Skyrizi (risankizumab)

$370.00$2,481.83

Skyrizi (risankizumab) is a medication used to treat adults with Plaque Psoriasis and Psoriatic Arthritis.

SKU: N/A Categories: ,

What is Skyrizi (risankizumab) for?

Skyrizi (risankizumab) is an interleukin-23 antagonist indicated to treat adults with:[1]

  • Plaque psoriasis that is moderate to severe in patients who are candidates for systemic therapy or phototherapy.
  • Active psoriatic arthritis

It is available prefilled syringe and pen containing 150 mg/mL of risankizumab.[1]

How does Skyrizi (risankizumab) work?

The active ingredient in Skyrizi, risankizumab, is a human monoclonal antibody, a type of protein, that binds to the cytokines interleukin (IL)-23. Cytokines play a role in signaling in a cell, especially in inflammation. Dysregulated production of and IL-23 were found to be very important in the development of specific diseases, such as psoriasis.[2]

By binding to IL-23, tildrakizumab will block their action, and thereby slow down inflammation.[1,2]

Where has Skyrizi (risankizumab) been approved?

Skyrizi (risankizumab) was approved by:

  • The Food and Drug Administration (FDA), USA
    • On April 23, 2019 to treat moderate to severe plaque psoriasis.[3]
    • On January 21, 2022 to treat active psoriatic arthritis.[4]
  • The European Medicines Agency (EMA)
    • On April 26, 2019 to treat moderate to severe plaque psoriasis.[5]
    • On November 22, 2021 to treat active psoriatic arthritis.[6]
  • Therapeutic Goods Administration (TGA)
    • On July 23, 2019 to treat moderate to severe plaque psoriasis.[7]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team. /contact-us

How is Skyrizi (risankizumab) taken?

The standard dosage is:[1]

  • The first two doses of 150 mg are given 4 weeks apart
  • The following doses are given every 12 weeks

Skyrizi is administered as an injection beneath the skin (subcutaneous).[1]

Skyrizi can be taken in a treatment center or at home after you receive training from your doctor.[1]

Complete information about Skyrizi (risankizumab) dosage (modification) and administration can be found in the official prescribing information listed in our references section.[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Skyrizi (risankizumab)?

Common adverse reactions

The most common side effects (≥1% of patients) listed in the prescribing information include:[1]

  • Upper respiratory infections
  • Headache
  • Fatigue
  • Injection site reactions
  • Tinea infections

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:[1]

  • Hypersensitivity reaction
  • Infections
  • Tuberculosis (TB)

Use in a specific population

Skyrizi (risankizumab) may harm your unborn baby when administered to a pregnant woman. Skyrizi may affect fertility in females and males who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.[1]

Pre-filled pen or syringe

Pre-filled syringe of 150 mg/ml, Pre-filled pen of 150 mg/ml